Review of current anti-obesity medication

Abstract

Although it is most widely accepted to lose weight by purely exercising and modifying diet, such a strategy often takes a relatively long time to work and may be inadequate for patients with other conditions, such as knee problems. The anti-obesity medications (AOMs) approved in the market are generally divided into two groups with either acting sites on peripheral digestive organs or on central nervous systems (CNS). Two representatives of these categories are Orlistat and Semaglutide. Especially, the GLP-1 receptor agonists (GLP-1 RAs), represented by Semaglutide, have a more promising future and more medications undergoing development.